LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$702.60 |
| 52 Week High | US$737.50 |
| 52 Week Low | US$334.60 |
| Beta | 0.37 |
| 1 Month Change | -0.62% |
| 3 Month Change | 21.77% |
| 1 Year Change | 107.38% |
| 3 Year Change | 345.81% |
| 5 Year Change | 563.83% |
| Change since IPO | 903.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.1% | -3.3% | -1.5% |
| 1Y | 107.4% | -30.8% | 0.9% |
Return vs Industry: LLY exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: LLY exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | €635.35b |
| Earnings (TTM) | €4.92b |
| Revenue (TTM) | €32.06b |
128.2x
P/E Ratio19.7x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$34.12b |
| Cost of Revenue | US$7.08b |
| Gross Profit | US$27.04b |
| Other Expenses | US$21.80b |
| Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 79.25% |
| Net Profit Margin | 15.36% |
| Debt/Equity Ratio | 233.4% |
How did LLY perform over the long term?
See historical performance and comparison